Literature DB >> 11594457

Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

G L Beatty1, Y Paterson.   

Abstract

Tumor immunity involves a concerted interplay between cytokines and effector cells. Extensive efforts have focused on understanding the roles of cytokines and their interactions with effector cells for the production of effective tumor immunity. One cytokine that is well recognized to play a central role in coordinating tumor immune responses is IFN-gamma. IFN-gamma exerts its biological effects through interaction with an IFN-gamma receptor that is ubiquitously expressed on nearly all cells. In this review, we discuss the positive and negative effects of IFN-gamma signaling in the tumor cell on tumor growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594457     DOI: 10.1385/IR:24:2:201

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  70 in total

Review 1.  Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma.

Authors:  L Kowalzick; U Weyer; P Lange; E W Breitbart
Journal:  Dermatologica       Date:  1990

2.  Antiangiogenic gene therapy.

Authors:  J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

3.  Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression.

Authors:  N K Ossina; A Cannas; V C Powers; P A Fitzpatrick; J D Knight; J R Gilbert; E M Shekhtman; L D Tomei; S R Umansky; M C Kiefer
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 4.  The biochemistry and cell biology of antigen processing and presentation.

Authors:  R N Germain; D H Margulies
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis.

Authors:  H Echchakir; M Bagot; G Dorothée; D Martinvalet; S Le Gouvello; L Boumsell; S Chouaib; A Bensussan; F Mami-Chouaib
Journal:  J Invest Dermatol       Date:  2000-07       Impact factor: 8.551

Review 6.  Immunological functions of macrophages and their regulation by interferons.

Authors:  J L Virelizier; F Arenzana-Seisdedos
Journal:  Med Biol       Date:  1985

Review 7.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

8.  Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon.

Authors:  J Kantor; R Tran; J Greiner; S Pestka; P B Fisher; J E Shively; J Schlom
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

9.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.

Authors:  T Nishimura; K Iwakabe; M Sekimoto; Y Ohmi; T Yahata; M Nakui; T Sato; S Habu; H Tashiro; M Sato; A Ohta
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

View more
  27 in total

Review 1.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

2.  Comprehensive network map of interferon gamma signaling.

Authors:  Mohd Younis Bhat; Hitendra S Solanki; Jayshree Advani; Aafaque Ahmad Khan; T S Keshava Prasad; Harsha Gowda; Saravanan Thiyagarajan; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2018-09-06       Impact factor: 5.782

3.  Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Authors:  Chengkuan Cai; Jingyuan Tang; Baixin Shen; Liucheng Ding; Yunpeng Shao; Zhengsen Chen; Yinchao Ma; Haoliang Xue; Zhongqing Wei
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

4.  Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.

Authors:  Janet F Piskurich; Carolyn A Gilbert; Brittany D Ashley; Mojun Zhao; Han Chen; Jian Wu; Sophia C Bolick; Kenneth L Wright
Journal:  Mol Immunol       Date:  2005-06-13       Impact factor: 4.407

5.  PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.

Authors:  Kevin P Nikitczuk; Rene S Schloss; Martin L Yarmush; Edmund C Lattime
Journal:  J Cancer Ther       Date:  2013-01-01

6.  MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Authors:  Mojun Zhao; Frederick L Flynt; Mei Hong; Han Chen; Carolyn A Gilbert; Nicole T Briley; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

7.  HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Authors:  Maciej Kmieciak; Keith L Knutson; Catherine I Dumur; Masoud H Manjili
Journal:  Eur J Immunol       Date:  2007-03       Impact factor: 5.532

8.  In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation.

Authors:  Saravana Kanagavelu; Seema Gupta; Xiaodong Wu; Sakhi Philip; Max M Wattenberg; James W Hodge; Mariluz D Couto; Kristina D Chung; Mansoor M Ahmed
Journal:  Radiat Res       Date:  2014-07-18       Impact factor: 2.841

Review 9.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

Review 10.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.